SCHEMBL862082

SCHEMBL862082

CC(C)CNc1ccn2ncc(C=C3NC(=O)NC3=O)c2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
POLB P06746 2/20 0.35
CSNK2B P67870 2/20 0.35
PIM1 P11309 4/20 0.35
PIM2 Q9P1W9 2/20 0.35
ALDH1A1 P00352 4/20 0.34
HPGD P15428 4/20 0.34
KDM4E B2RXH2 6/20 0.34
MAPT P10636 4/20 0.34
GAA P10253 2/20 0.34
PKM P14618 1/20 0.34
LMNA P02545 3/20 0.33
RET P07949 1/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
NCOA1 Q15788 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
CGAS Q8N884 1/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12979114 1.00 MEN1 (0.36) MEN1KMT2APOLBCSNK2BPIM1
SCHEMBL862081 1.00 MEN1 (0.36) MEN1KMT2APOLBCSNK2BPIM1
SCHEMBL12979184 0.86 MEN1 (0.38) MEN1KMT2APOLBCSNK2BALDH1A1
SCHEMBL860772 0.86 MEN1 (0.38) MEN1KMT2APOLBCSNK2BALDH1A1
SCHEMBL860773 0.86 MEN1 (0.38) MEN1KMT2APOLBCSNK2BALDH1A1
SCHEMBL3483136 0.84 PIM1 (0.40) CSNK2BPIM1PIM2ALDH1A1HPGD
SCHEMBL3483134 0.84 PIM1 (0.40) CSNK2BPIM1PIM2ALDH1A1HPGD
SCHEMBL12979217 0.84 PIM1 (0.40) CSNK2BPIM1PIM2ALDH1A1HPGD
SCHEMBL860204 0.80 PIM1 (0.37) CSNK2BPIM1PIM2RET
SCHEMBL860933 0.79 FYN (0.43) MEN1KMT2APOLBPIM1NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
EP-2432473-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 MEN1 3936/4885KMT2A 1758/4885POLB 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.